{"id":"rh-endostatin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Proteinuria"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL4297747","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endostatin is an endogenous angiogenesis inhibitor derived from collagen XVIII. Rh-endostatin (recombinant human endostatin) works by suppressing vascular endothelial growth factor (VEGF) signaling and inhibiting endothelial cell proliferation and migration, preventing the formation of new blood vessels that tumors require for growth and metastasis.","oneSentence":"Rh-endostatin inhibits angiogenesis by blocking new blood vessel formation, thereby starving tumors of their blood supply.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:55.031Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT06562673","phase":"PHASE1, PHASE2","title":"Intra-arterial Cisplatin Plus Rh-endostatin Combined With Systematic Chemotherapy in Osteosarcoma","status":"COMPLETED","sponsor":"Shanghai 6th People's Hospital","startDate":"2024-12-03","conditions":"Osteosarcoma, Bone Cancer","enrollment":10},{"nctId":"NCT06747169","phase":"PHASE2","title":"Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Jian-Guo Zhou, MD, PhD","startDate":"2024-12-17","conditions":"Squamous Non-Small Cell Lung Cancer SqNSCLC","enrollment":32},{"nctId":"NCT05278715","phase":"PHASE2","title":"Modified CV Regimen in Optic Pathway Glioma","status":"RECRUITING","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2022-04-13","conditions":"Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma","enrollment":75},{"nctId":"NCT04659421","phase":"PHASE2","title":"Study of Recombinant Human Endostatin Combined With CV Regimen in the Treatment of Pediatric Low-grade Gliomas","status":"COMPLETED","sponsor":"Beijing Sanbo Brain Hospital","startDate":"2020-11-03","conditions":"Low-grade Glioma, Pediatric Brain Tumor","enrollment":60},{"nctId":"NCT04613284","phase":"PHASE4","title":"Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-12-01","conditions":"Lung Cancer","enrollment":97},{"nctId":"NCT04094909","phase":"PHASE2","title":"Rh-endostatin Combined With Chemotherapy and Pembrolizumab for Advanced NSCLC","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2020-02-06","conditions":"Staging IV NSCLC","enrollment":186},{"nctId":"NCT03706703","phase":"PHASE2","title":"Rh-Endostatin (Endostar®) Continuous Intravenous Infusion","status":"UNKNOWN","sponsor":"Affiliated Cancer Hospital & Institute of Guangzhou Medical University","startDate":"2018-10-01","conditions":"Lung Cancer","enrollment":50},{"nctId":"NCT03208335","phase":"PHASE2","title":"Recombinant Human Endostatin(Rh-endostatin) Combine With Radiotherapy in the Treatment of Hepatocellular Carcinoma(HCC)","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-01-01","conditions":"Hepatocellular Carcinoma","enrollment":61},{"nctId":"NCT03095079","phase":"PHASE2","title":"Rh-endostatin in Combination With Dacarbazine and Cisplatin as the First Line Therapy for Metastatic Melanoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2016-10","conditions":"Melanoma","enrollment":70},{"nctId":"NCT03008109","phase":"PHASE3","title":"Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC","status":"UNKNOWN","sponsor":"Zaiwen Fan","startDate":"2017-02","conditions":"Advanced Cancer, Lung Cancer, Nonsmall Cell","enrollment":80},{"nctId":"NCT02748772","phase":"PHASE3","title":"Application of Two Anti-angiogenesis Drugs Combined With Chemotherapy in Advanced Colorectal Cancer Under the Background of Precision Medical","status":"UNKNOWN","sponsor":"The First People's Hospital of Hefei","startDate":"2016-01","conditions":"Colorectal Neoplasms","enrollment":148},{"nctId":"NCT02375022","phase":"PHASE2","title":"Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-03","conditions":"Lung Cancer","enrollment":10},{"nctId":"NCT02283476","phase":"PHASE3","title":"The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.","status":"UNKNOWN","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2014-11","conditions":"Lung Cancer","enrollment":200},{"nctId":"NCT02008422","phase":"PHASE3","title":"Clinical Study of Endostar Injection Concomitant With SOX Protocols to Treat Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Tang Xushan","startDate":"2013-08","conditions":"Gastric Cancer","enrollment":120},{"nctId":"NCT02001168","phase":"PHASE3","title":"Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin on Non-small Cell Lung Cancer in PhaseⅠB","status":"UNKNOWN","sponsor":"Xinjiang Medical University","startDate":"2013-10","conditions":"Non-small Cell Lung Cancer","enrollment":392},{"nctId":"NCT01099124","phase":"NA","title":"Study of M2ES With Paclitaxel/Carboplatin (TC Regimen) in Advanced Non Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2009-12","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT01211002","phase":"PHASE4","title":"Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2010-10","conditions":"Non-small Cell Lung Cancer","enrollment":170},{"nctId":"NCT00813332","phase":"PHASE4","title":"Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2008-10","conditions":"Advanced NSCLC, Recurrent NSCLC","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":94,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pembrolizumab","carboplatin","cisplatin","pemetrexed","[nab]-paclitaxel"],"phase":"phase_3","status":"active","brandName":"Rh-endostatin","genericName":"Rh-endostatin","companyName":"Guangzhou Institute of Respiratory Disease","companyId":"guangzhou-institute-of-respiratory-disease","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rh-endostatin is used in combination with thoracic irradiation of 50 Gy and possibly other treatments for the conditions studied, including Lung Cancer, Non Small Cell Lung Cancer, Colorectal Neoplasms, and Non-small Cell Lung Cancer. The exact mechanism of Rh-endostatin is not specified in the provided facts, but it is listed as recombinant human endostatin (Endostar) in ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":25,"withResults":10},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}